David Sheehan is the Founder, President, and CEO.  Nucleus Biologics is the only Excipient GMP custom media and buffer company for cell and gene therapy and offers NB-Lux™, a digital platform for media and buffer ordering, and NB-AIR™, an AI platform that creates formulas based on cell type, and Krakatoa, the first pod-based, point-of-use benchtop media and buffer mixing system. Prior to Nucleus Biologics, Dave was COO of Volcano Corporation, a publicly held life sciences company that was sold to Philips for $1.2 billion. Previous to Volcano, Dave was the CEO or in leadership positions at various companies including Baxter, Digirad and Haemonetics. Dave holds an MBA from The Tuck School at Dartmouth College and a BS in Mechanical Engineering from Worcester Polytechnic Institute.